Terumo Neuro Unveils SOFIA™ Flow 88 Neurovascular Catheter with EMEA Performance Data
Terumo Neuro Launches SOFIA™ Flow 88 Catheter
On September 3, 2025, Terumo Neuro, a leader in neurovascular innovations and a wholly-owned subsidiary of Terumo Corporation, introduced the SOFIA™ Flow 88 neurovascular aspiration catheter at the 17th Annual Congress of the European Society of Minimally Invasive Neurological Therapy (ESMINT 2025). This launch coincided with the release of significant real-world physician preference data from the EMEA region, highlighting the catheter's strong performance in various clinical settings.
Key Highlights of the SOFIA™ Flow 88
The data showcased at ESMINT provided compelling evidence of the SOFIA Flow 88's capabilities, especially in stroke intervention practices. Conducted across 70 procedures in 16 hospitals involving 31 physicians, the preference test yielded impressive results:
- - A staggering 83% of physicians reported that the SOFIA Flow 88 was able to reliably reach target locations, even in anatomically challenging cases, with 76% of procedures occurring in the Internal Carotid Artery (ICA) or higher.
- - 100% of the physicians rated the catheter as performing
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.